[摘要]"心臟起搏是治療竇房結(jié)功能障礙或房室傳導(dǎo)阻滯所致心動(dòng)過緩的有效方法。傳統(tǒng)的右心室心尖起搏可導(dǎo)致電和機(jī)械不同步,從而增加房性心律失常和心力衰竭的風(fēng)險(xiǎn),高比例的右心室間隔部位起搏也可增加心律失常和心力衰竭的風(fēng)險(xiǎn)。由中國(guó)人首創(chuàng)的左束支起搏技術(shù),近年來(lái)得到國(guó)內(nèi)外學(xué)者的廣泛關(guān)注,諸多研究正在開展,取得日新月異的研究成果。作為一種生理性的起搏新策略,左束支起搏技術(shù)繞過病理性阻滯區(qū)域直接激動(dòng)左束支,相較右心室起搏可使患者獲得更生理的起搏方式,且可成功糾正由左束支傳導(dǎo)阻滯引起的心力衰竭,也具有更好的安全性和穩(wěn)定性,可顯著改善患者的預(yù)后。本文通過回顧該前沿技術(shù)的研究動(dòng)態(tài),對(duì)國(guó)內(nèi)外左束支起搏技術(shù)的最新研究進(jìn)展進(jìn)行綜述。
[關(guān)鍵詞]"左束支起搏;生理性起搏;臨床療效;心臟起搏并發(fā)癥
[中圖分類號(hào)]"R541""""[文獻(xiàn)標(biāo)識(shí)碼]"A""""[DOI]"10.3969/j.issn.1673-9701.2024.09.030
心臟傳導(dǎo)疾病是一種因傳導(dǎo)系統(tǒng)完整性發(fā)生病理性損害而導(dǎo)致的常見病,可通過心律失常引起血流動(dòng)力學(xué)不穩(wěn)定,以致產(chǎn)生嚴(yán)重危害,甚至危及患者的生命。盡管心臟傳導(dǎo)疾病的病理生理機(jī)制多種多樣,但在無(wú)可逆原因的情況下,傳統(tǒng)的心臟起搏仍是治療癥狀性心動(dòng)過緩的唯一有效方法[1]。右心室心尖部起搏(right"ventricular"apical"pacing,RVAP)已在臨床廣泛開展超過50年。然而,RVAP的電激動(dòng)順序與正常生理起搏順序相反,可導(dǎo)致異常的電活動(dòng)和不協(xié)調(diào)的心室收縮,引起心電活動(dòng)和機(jī)械活動(dòng)的不同步,使心臟收縮效率顯著降低,且左心室延遲收縮節(jié)段的室壁厚度比早期收縮節(jié)段更厚,易導(dǎo)致心臟病理性重構(gòu)。由于這些影響,RVAP與心房顫動(dòng)、心力衰竭及心血管死亡的風(fēng)險(xiǎn)增加有關(guān)[2]。而右心室其他部位的起搏(如右心室間隔或流出道起搏)是否優(yōu)于RVAP尚存在爭(zhēng)議。研究表明右心室間隔起搏在血流動(dòng)力學(xué)、收縮模式和電活動(dòng)方面并沒有顯著益處,且右心室心尖起搏患者和非心尖起搏患者的左心室射血分?jǐn)?shù)也無(wú)明顯差異[3-4]。此外,使用雙心室起搏(biventricular"pacing,BVP)的心臟再同步化治療(cardiac"resynchronization"therapy,CRT)可改善伴有左束支傳導(dǎo)阻滯的收縮性心力衰竭患者的左心室重塑,提高運(yùn)動(dòng)耐量,降低心力衰竭住院率和死亡率,曾是心力衰竭治療史上具有里程碑意義的起搏方式[5]。但BVP非完全生理,其預(yù)先激動(dòng)的是左心室心肌而非特殊傳導(dǎo)系統(tǒng),隨后觀察到其在很多心力衰竭患者中的效果仍不理想[6]。
因此,人們對(duì)直接激動(dòng)心臟特殊傳導(dǎo)系統(tǒng)的生理性起搏技術(shù)越來(lái)越感興趣。其中希氏束起搏(his"bundle"pacing,HBP)是最早被研究也是最常用、最生理的起搏方式。希氏束作為心臟傳導(dǎo)系統(tǒng)的組成部分,選擇其作為起搏部位可產(chǎn)生和自身電傳導(dǎo)一致的正常雙心室電激動(dòng),從而實(shí)現(xiàn)雙心室激動(dòng)的同步性,多項(xiàng)研究證明該技術(shù)具有可行性和臨床益處[7-9]。然而,盡管作為目前最為生理性的一種起搏方式,HBP依然有一定的局限性。由于希氏束的直徑極短,僅為1~2mm,所以對(duì)希氏束的準(zhǔn)確定位相對(duì)困難,導(dǎo)致患者植入成功率相對(duì)較低;另外由于個(gè)體差異性,患者希氏束的位置和周圍纖維化情況不同,5%~10%的患者可出現(xiàn)起搏閾值高且不穩(wěn)定的情況;此外在植入過程中可致希氏束受損、起搏遠(yuǎn)端可發(fā)生心臟傳導(dǎo)阻滯等問題,使其遠(yuǎn)期的穩(wěn)定性及安全性仍令人擔(dān)憂[7,"10]。為解決以上問題,近些年出現(xiàn)生理性起搏的新技術(shù),即左束支起搏(left"bundle"brunch"pacing,LBBP)[11-12]。
LBBP于2017年由黃偉劍教授團(tuán)隊(duì)首次報(bào)道,其通過繞過病理性阻滯區(qū)域?qū)ψ笫е苯蛹?dòng)而成功糾正由左束支傳導(dǎo)阻滯(left"bundle"branch"block,LBBB)引起的心力衰竭,使患者的癥狀及預(yù)后得到顯著改善,在臨床得到廣泛應(yīng)用[13]。作為一種新興的生理性起搏技術(shù),LBBP可避免HBP及右心室起搏等的許多局限性,是目前起搏治療領(lǐng)域研究的熱點(diǎn)。鑒于近年來(lái)國(guó)內(nèi)外越來(lái)越多的學(xué)者對(duì)其進(jìn)行研究,為便于獲取該前沿技術(shù)的研究動(dòng)態(tài),本文從LBBP的適應(yīng)證、臨床療效、長(zhǎng)期安全性和并發(fā)癥等方面對(duì)國(guó)內(nèi)外關(guān)于LBBP技術(shù)的最新研究進(jìn)展進(jìn)行綜述。
1""LBBP的最新定義及奪獲標(biāo)準(zhǔn)
LBBP最新定義:經(jīng)靜脈途徑將導(dǎo)線從右心室間隔面深擰穿間隔至左心室間隔面內(nèi)膜下的左束支區(qū)域,起搏奪獲左束支主干或左前、左后分支或更遠(yuǎn)端的左側(cè)浦肯野纖維網(wǎng),達(dá)到跨越阻滯部位,保持左心室電同步[14]。目前左束支奪獲最新標(biāo)準(zhǔn):①起搏QRS波呈右束支傳導(dǎo)阻滯(right"bundle"branch"block,RBBB)樣形態(tài);②記錄到左束支(left"bundle"branch,LBB)電位;③短而恒定的左心室激動(dòng)時(shí)間,通常測(cè)量V4~V6導(dǎo)聯(lián)中起搏釘?shù)絉波峰值之間的間隔;④在閾值測(cè)試期間顯示從非選擇性LBB奪獲到選擇性LBB奪獲或非選擇性LBB奪獲到僅左心室心肌奪獲的轉(zhuǎn)變[14-15]。
2""LBBP的適應(yīng)證及臨床療效
左束支被致密的心肌組織包圍,其厚實(shí)的帶狀結(jié)構(gòu)為起搏提供更大的靶區(qū)。因此與傳統(tǒng)CRT相比,LBBP具有更為廣泛的臨床適應(yīng)證。LBBP有望通過BVP的起搏方式替代大部分傳統(tǒng)CRT治療伴有心室不同步的心力衰竭患者,并可能是典型LBBB患者的最佳選擇[16]。最近一項(xiàng)研究不僅證明LBBP可糾正LBBB并維持心室電和機(jī)械再同步,且證明LBBP在11例CRT適應(yīng)證患者中的臨床效果顯著[17]。對(duì)無(wú)起搏指征且QRS間期狹窄的收縮性心力衰竭患者是不適用CRT的(由于其在2個(gè)非生理部位起搏導(dǎo)致心室不同步)[18];而LBBP通過天然傳導(dǎo)系統(tǒng)可實(shí)現(xiàn)更好的心室同步,是該類患者更好的選擇。同樣,在伴有LBBB或RBBB的癥狀性心動(dòng)過緩或心室起搏比例高的患者中,LBBP因能比右心室起搏提供更多的生理性心室激動(dòng)而成為首選起搏方式。因此LBBP相對(duì)具有更廣泛的臨床適應(yīng)證。
目前大量前期研究已證實(shí)LBBP在技術(shù)及臨床上的諸多優(yōu)勢(shì)。研究表明LBBP可獲得較BVP更好的心室電和機(jī)械同步[19]。研究發(fā)現(xiàn)LBBP可維持與HBP相當(dāng)?shù)耐叫氖壹?dòng),獲得較好的血流動(dòng)力學(xué)效果,從而改善心力衰竭癥狀[19-20]。LBBP的優(yōu)點(diǎn)是起搏部位可繞過心臟傳導(dǎo)系統(tǒng)的病變或易損區(qū)(如房室結(jié)、希氏束和LBB近端),為需要心室起搏的心動(dòng)過緩或心力衰竭患者提供接近生理的傳導(dǎo)系統(tǒng)起搏[13,21-22]。另一個(gè)令人驚喜的發(fā)現(xiàn)是LBBP產(chǎn)生窄QRS波,起搏QRS間期與自身QRS間期相似,持續(xù)時(shí)間通常lt;130ms,比右心室起搏時(shí)短得多,使其更有可能替代HBP被用于癥狀性心動(dòng)過緩患者的起搏治療[22-23]。與HBP相比,由于起搏部位位于間隔心肌組織中,LBBP具有更低(lt;1.0V)和更穩(wěn)定的起搏閾值,這可提高設(shè)備壽命,且可避免傳統(tǒng)BVP靜脈造影和避免使用第3根起搏導(dǎo)線[20]。同時(shí),LBBP相比HBP具有更高的感知R波,簡(jiǎn)化了起搏管理。此外,LBBP植入通常比HBP更簡(jiǎn)單、更快。經(jīng)室間隔技術(shù)使LBBP比HBP更容易實(shí)施,且LBB廣泛分布在左心室間隔心內(nèi)膜下,導(dǎo)線放置所需的精準(zhǔn)度要求也較低[22-24]。這提示對(duì)于HBP失敗的患者,LBBP不失為一個(gè)更合理的選擇。
3""LBBP的長(zhǎng)期安全性及并發(fā)癥
研究表明LBBP技術(shù)具有較高的安全性和穩(wěn)定性[23,"25-26]。LBBP可提供穩(wěn)定可靠的導(dǎo)線參數(shù),在短期和中期隨訪中具有更長(zhǎng)的電池壽命[25,"27]。LBBP不再需要備用右心室導(dǎo)線,且簡(jiǎn)化植入設(shè)備參數(shù)選擇設(shè)置,隨訪時(shí)閾值很少升高[28]。重要的是LBBP的并發(fā)癥發(fā)生率較低。一項(xiàng)對(duì)115例具有LBB電位和QRS持續(xù)時(shí)間lt;120ms的患者進(jìn)行的研究發(fā)現(xiàn),所有患者均成功完成LBBP導(dǎo)線植入,在6個(gè)月的隨訪過程中均沒有發(fā)生嚴(yán)重的并發(fā)癥(如移位、感染或腦卒中等)[29]。目前研究顯示LBBP安全植入的成功率為81%~93%[23,"30]。并發(fā)癥發(fā)生率最高僅為6%,包括3例在植入后24h內(nèi)發(fā)生的導(dǎo)線移位和3例左心室間隔穿孔[30]。LBBP術(shù)后患者心功能得到有效改善,Li等[20]報(bào)道33例房室傳導(dǎo)阻滯(atrioventricular"block,AVB)患者在LBBP術(shù)后3個(gè)月的隨訪時(shí)間內(nèi)心功能維持良好。幾項(xiàng)中/長(zhǎng)期觀察性研究揭示LBBP在隨訪期間可保持穩(wěn)定的起搏和心電圖參數(shù)[25-27,"31],且有研究結(jié)果支持LBBP導(dǎo)聯(lián)解剖位置的長(zhǎng)期穩(wěn)定性[26]。
LBBP的常見并發(fā)癥包括束支損傷、間隔穿孔、閾值增加及失奪獲、電極脫位、導(dǎo)線損壞、心包積液、血栓形成、瓣膜損傷及室間隔血腫等。其中室間隔穿孔和血栓栓塞是LBBP最常見的并發(fā)癥。間隔穿孔包括急性和晚期導(dǎo)線穿孔,LBBP植入后有3%的患者出現(xiàn)急性穿孔[30]。若出現(xiàn)R波振幅減小、奪獲閾值增加或單極阻抗立即降至500Ω以下表明發(fā)生急性導(dǎo)線穿孔。評(píng)估基底室間隔的厚度和導(dǎo)線長(zhǎng)度是避免穿孔的有效方法。在發(fā)生急性間隔穿孔時(shí),需在不同位置重新植入導(dǎo)線。晚期間隔穿孔很少見,其特征與急性間隔穿孔相似[32]。監(jiān)測(cè)起搏圖形、阻抗和心肌損傷電流可有效預(yù)防室間隔穿孔,一旦發(fā)生室間隔穿孔并發(fā)癥,經(jīng)皮介入封堵治療或許是有效方法[33]。同時(shí)LBBP還可引起右束支和間隔動(dòng)脈損傷等并發(fā)癥,將導(dǎo)線放置在希氏束區(qū)域下方至少10mm處,可最大限度減少該并發(fā)癥[34]。此外,加強(qiáng)術(shù)后隨訪、及時(shí)監(jiān)測(cè)起搏參數(shù)等對(duì)LBBP術(shù)后短期和長(zhǎng)期并發(fā)癥的預(yù)防有重要作用。由此可見,LBBP植入成功率高,并發(fā)癥發(fā)生率較低,各方面具有相對(duì)長(zhǎng)期的穩(wěn)定性,是一項(xiàng)安全可行的起搏技術(shù)。
4""討論與展望
希氏束是連接房室結(jié)和束分支的細(xì)圓柱形束,形成左束支的纖維可產(chǎn)生一個(gè)交織的纖維網(wǎng)絡(luò),覆蓋中隔的下1/3部分,可避免當(dāng)LBB的一個(gè)分區(qū)出現(xiàn)傳導(dǎo)阻滯時(shí)QRS變寬。左束支的解剖特征決定LBBP作為潛在生理起搏方式的可行性。
隨著越來(lái)越多的生理性心臟起搏模式能更好地實(shí)現(xiàn)心臟再同步,具有良好起搏參數(shù)和臨床療效的LBBP目前為國(guó)內(nèi)外研究的熱點(diǎn)。LBBP通過激動(dòng)天然傳導(dǎo)系統(tǒng)使心室除極接近生理狀態(tài),可提供生理性心室激動(dòng)模式,有助于維持令人滿意的左心室同步性并產(chǎn)生良好的血流動(dòng)力學(xué)效應(yīng),可為遠(yuǎn)端浦肯野系統(tǒng)完整的患者提供真正的生理起搏策略,是一種很有前景的傳統(tǒng)右心室起搏替代方法,甚至有可能成為未來(lái)的首選策略。由于LBBP應(yīng)用時(shí)間較短,目前仍在很多方面缺乏足夠認(rèn)識(shí),包括手術(shù)的長(zhǎng)期安全性、有效性和合適的患者群體等,還需更多、更大規(guī)模的前瞻性臨床試驗(yàn)和機(jī)制研究以確定最有可能受益的患者群體。
利益沖突:所有作者均聲明不存在利益沖突。
[參考文獻(xiàn)]
[1] HERWEG"B,"WELTER-FROST"A,"WILSON"II"D"R,"et"al."Conduction"system"pacing"for"cardiac"resynchronization"therapy[J]."Card"Electrophysiol"Clin,"2022,"14(2):"297–310.
[2] SWEENEY"M"O,"HELLKAMP"A"S,"ELLENBOGEN"K"A,"et"al."Adverse"effect"of"ventricular"pacing"on"heart"failure"and"atrial"fibrillation"among"patients"with"normal"baseline"QRS"duration"in"a"clinical"trial"of"pacemaker"therapy"for"sinus"node"dysfunction[J]."Circulation,"2003,"107(23):"2932–2937.
[3] MILLS"R"W,"CORNELUSSEN"R"N,"MULLIGAN"L"J,"et"al."Left"ventricular"septal"and"left"ventricular"apical"pacing"chronically"maintain"cardiac"contractile"coordination,"pump"function"and"efficiency[J]."Circ"Arrhythm"Electrophysiol,"2009,"2(5):"571–579.
[4] HUSSAIN"M"A,"FURUYA-KANAMORI"L,"KAYE"G,"et"al."The"effect"of"right"ventricular"apical"and"nonapical"pacing"on"the"short-"and"long-term"changes"in"left"ventricular"ejection"fraction:"A"systematic"review"and"Meta-analysis"of"randomized-controlled"trials[J]."Pacing"Clin"Electrophysiol,"2015,"38(9):"1121–1136.
[5] CLELAND"J"G,"DAUBERT"J"C,"ERDMANN"E,"et"al."The"effect"of"cardiac"resynchronization"on"morbidity"and"mortality"in"heart"failure[J]."N"Engl"J"Med,"2005,"352(15):"1539–1549.
[6] DAUBERT"C,"BEHAR"N,"MARTINS"R"P,"et"al."Avoiding"non-responders"to"cardiac"resynchronization"therapy:"A"practical"guide[J]."Eur"Heart"J,"2017,"38(19):"1463–1472.
[7] LUSTGARTEN"D"L,"CRESPO"E"M,"ARKHIPOVA-"JENKINS"I,"et"al."His-bundle"pacing"versus"biventricular"pacing"in"cardiac"resynchronization"therapy"patients:"A"crossover"design"comparison[J]."Heart"Rhythm,"2015,"12(7):"1548–1557.
[8] HUANG"W,"SU"L,"WU"S,"et"al."Long-term"outcomes"of"His"bundle"pacing"in"patients"with"heart"failure"with"left"bundle"branch"block[J]."Heart,"2019,"105(2):"137–143.
[9] ABDELRAHMAN"M,"SUBZPOSH"F"A,"BEER"D,"et"al."Clinical"outcomes"of"his"bundle"pacing"compared"to"right"ventricular"pacing[J]."J"Am"Coll"Cardiol,"2018,"71(20):"2319–2330.
[10] SUBZPOSH"F"A,"VIJAYARAMAN"P."Long-term"results"of"His"bundle"pacing[J]."Card"Electrophysiol"Clin,"2018,"10(3):"537–542.
[11] SU"L,"ELLENBOGEN"K"A,"HUANG"W."Left"bundle"branch"pacing:"How"I"do"it?[J]."Card"Electrophysiol"Clin,"2022,"14(2):"165–179.
[12] GENG"J,"JIANG"Z,"ZHANG"S,"et"al."Reversible"T-wave"inversions"during"left"bundle"branch"area"pacing[J]."Kardiol"Pol,"2022,"80(10):"1002–1009.
[13] HUANG"W,"SU"L,"WU"S,"et"al."A"novel"pacing"strategy"with"low"and"stable"output:"Pacing"the"left"bundle"branch"immediately"beyond"the"conduction"block[J]."Can"J"Cardiol,"2017,"33(12):"1736.
[14] HUANG"W,"CHEN"X,"SU"L,"et"al."A"beginner’s"guide"to"permanent"left"bundle"branch"pacing[J]."Heart"Rhythm,"2019,"16(12):"1791–1796.
[15] GAO"M"Y,"TIAN"Y,"SHI"L,"et"al."Electrocardiographic"morphology"during"left"bundle"branch"area"pacing:"Characteristics,"underlying"mechanisms,"and"clinical"implications[J]."Pacing"Clin"Electrophysiol,"2020,"43(3):"297–307.
[16] LI"Y,"YAN"L,"DAI"Y,"et"al."Feasibility"and"efficacy"of"left"bundle"branch"area"pacing"in"patients"indicated"for"cardiac"resynchronization"therapy[J]."Europace,"2020,"22(Suppl_2):"54–60.
[17] ZHANG"W,"HUANG"J,"QI"Y,"et"al."Cardiac"resynchronization"therapy"by"left"bundle"branch"area"pacing"in"patients"with"heart"failure"and"left"bundle"branch"block[J]."Heart"Rhythm,"2019,"16(12):"1783–1790.
[18] PLOUX"S,"ESCHALIER"R,"WHINNETT"Z"I,"et"al."Electrical"dyssynchrony"induced"by"biventricular"pacing:"Implications"for"patient"selection"and"therapy"improvement[J]."Heart"Rhythm,"2015,"12(4):"782–791.
[19] WANG"Y,"ZHU"H,"HOU"X,"et"al."Randomized"trial"of"left"bundle"branch"vs"biventricular"pacing"for"cardiac"resynchronization"therapy[J]."J"Am"Coll"Cardiol,"2022,"80(13):"1205–1216.
[20] LI"X,"LI"H,"MA"W,"et"al."Permanent"left"bundle"branch"area"pacing"for"atrioventricular"block:"Feasibility,"safety,"and"acute"effect[J]."Heart"Rhythm,"2019,"16(12):"1766–1773.
[21] TENG"A"E,"MASSOUD"L,"AJIJOLA"O"A."Physiological"mechanisms"of"QRS"narrowing"innbsp;bundle"branch"block"patients"undergoing"permanent"His"bundle"pacing[J]."J"Electrocardiol,"2016,"49(5):"644–648.
[22] CHEN"K,"LI"Y,"DAI"Y,"et"al."Comparison"of"electrocardiogram"characteristics"and"pacing"parameters"between"left"bundle"branch"pacing"and"right"ventricular"pacing"in"patients"receiving"pacemaker"therapy[J]."Europace,"2019,"21(4):"673–680.
[23] LI"Y,"CHEN"K,"DAI"Y,"et"al."Left"bundle"branch"pacing"for"symptomatic"bradycardia:"Implant"success"rate,"safety,"and"pacing"characteristics[J]."Heart"Rhythm,"2019,"16(12):"1758–1765.
[24] ANDERSON"R"H,"YANNI"J,"BOYETT"M"R,"et"al."The"anatomy"of"the"cardiac"conduction"system[J]."Clin"Anat,"2009,"22(1):"99–113.
[25] SU"L,"WANG"S,"WU"S,"et"al."Long-term"safety"and"feasibility"of"left"bundle"branch"pacing"in"a"large"single-center"study[J]."Circ"Arrhythm"Electrophysiol,"2021,"14(2):"e009261.
[26] HU"Q,"LU"W,"CHEN"K,"et"al."Long-term"follow-up"results"of"patients"with"left"bundle"branch"pacing"and"exploration"for"potential"factors"affecting"cardiac"function[J]."Front"Physiol,"2022,"13:"996640.
[27] PADALA"S"K,"MASTER"V"M,"TERRICABRAS"M,"et"al."Initial"experience,"safety,"and"feasibility"of"left"bundle"branch"area"pacing:"A"multicenter"prospective"study[J]."JACC"Clin"Electrophysiol,"2020,"6(14):"1773–1782.
[28] BAKELANTS"E,"BURRI"H."Troubleshooting"programming"of"conduction"system"pacing[J]."Arrhythm"Electrophysiol"Rev,"2021,"10(2):"85–90.
[29] SU"L,"XU"T,"CAI"M,"et"al."Electrophysiological"characteristics"and"clinical"values"of"left"bundle"branch"current"of"injury"in"left"bundle"branch"pacing[J]."J"Cardiovasc"Electrophysiol,"2020,"31(4):"834–842.
[30] VIJAYARAMAN"P,"SUBZPOSH"F"A,"NAPERKOWSKI"A,"et"al."Prospective"evaluation"of"feasibility"and"electrophysiologic"and"echocardiographic"characteristics"of"left"bundle"branch"area"pacing[J]."Heart"Rhythm,"2019,"16(12):"1774–1782.
[31] SHARMA"P"S,"PATEL"N"R,"RAVI"V,"et"al."Clinical"outcomes"of"left"bundle"branch"area"pacing"compared"to"right"ventricular"pacing:"Results"from"the"Geisinger-"Rush"Conduction"System"Pacing"Registry"[J]."Heart"Rhythm,"2022,"19(1):"3–11.
[32] RAVI"V,"LARSEN"T,"OOMS"S,"et"al."Late-onset"interventricular"septal"perforation"from"left"bundle"branch"pacing[J]."HeartRhythm"Case"Rep,"2020,"6(9):"627–631.
[33] BRYNIARSKI"L,"OPOLSKI"M"P,"WóJCIK"J,"et"al."Chronic"total"occlusion"percutaneous"coronary"intervention"in"everyday"clinical"practice-An"expert"opinion"of"the"Association"of"Cardiovascular"Interventions"of"the"Polish"Cardiac"Society[J]."Postepy"Kardiol"Interwencyjnej,"2021,"17(1):"6–20.
[34] PONNUSAMY"S"S,"VIJAYARAMAN"P."Aborted"ST-"elevation"myocardial"infarction-An"unusual"complication"of"left"bundle"branch"pacing[J]."HeartRhythm"Case"Rep,"2020,"6(8):"520–522.
(收稿日期:2023–03–19)
(修回日期:2024–03–12)